Reaction
Human Ehrlichiosis reporting signals
As of the last recalculation, Human Ehrlichiosis appears in 198 FAERS reports alongside 11 co-occurring drug terms. The strongest observed disproportionality signal is VALGANCICLOVIR HYDROCHLORIDE POWDER, (PRR 473.1).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Valganciclovir Hydrochloride Powder, | 43 | 473.1 | 474.8 |
| Valganciclovir | 49 | 362.7 | 363.7 |
| Valganciclovir Hydrochloride | 49 | 362.7 | 363.7 |
| Basiliximab | 22 | 221.1 | 221.5 |
| Sirolimus | 18 | 154.4 | 154.6 |
| Mycophenilic Acid | 24 | 138.4 | 138.6 |
| Tacrolimus Ointment 0.1% | 86 | 127.6 | 127.7 |
| Tacrolimus Extended-Release Capsules | 86 | 127.2 | 127.3 |
| Mycophenolic Acid | 28 | 106.9 | 107.0 |
| Anti-Thymocyte Globulin (Rabbit) | 6 | 80.6 | 80.7 |
| Cefepime | 8 | 61.1 | 61.1 |